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culated. Per patient per month (PPPM) utilization rates were calculated based on
inpatient, outpatient and prescription data, and costs were estimated using Medi-
care reimbursement rates and Average Wholesale Price. RESULTS: A total of 5741
patientsmet the inclusion criteria. At least one HF re-hospitalizationwas observed
in 25% of patients, representing 85% of all-cause hospitalizations. Mean HF hos-
pital length of stay was 6.7 days at IH and 7.2 days at fourth HF re-hospitalization.
IH was most costly ($12,426) relative to the mean cost per subsequent HF re-hos-
pitalization ($9,832). HF re-hospitalization rates peaked at 0.062 PPPM 3-6 months
post IH. All-cause and HF-related outpatient visit rates peaked at 4.1 and 0.65 visits
PPPM, respectively, within threemonths after IH.Mean outpatient visit cost ranged
from$668 (0-3months) to $224 (18-24months post IH). Total pharmacy costs varied
from $593 PPPM (baseline period) to $848 PPPM (0-3 months post IH); of these,
cardiovascular drugs accounted for about one third ranging from $162 (baseline) to
$221 PPPM (0-3 months post IH). CONCLUSIONS: Treating elderly chronic HF pa-
tients is resource intensive and costly. Utilization and cost peak in the first three
months post IH. New interventions to improve health outcomes in the elderly HF
population hold the potential to decrease post IH resource utilization and save
costs.
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OBJECTIVES: Patients undergoing total knee or hip replacement are at high risk of
experiencing venous thromboembolism (VTE) - deep vein thrombosis (DVT) and
pulmonary embolism (PE), therefore, the aimof this studywas to estimate resource
utilization and associated costs of VTE following TKR under SUS perspective.
METHODS:Data analysis was conducted through a review of a government admin-
istrative claims database (DATASUS). A cohort of patients who underwent TKR
surgery in the public healthcare systemwas defined (1/2010 - 9/2010) and followed
for 6 months after surgery. Data regarding total hospitalization costs were com-
pared for patients who didn’t present complications with patients who presented
VTE events.RESULTS:A total of 4736 patientswere identified between January 2010
to September 2010 with average age of 65,6 years (SD 10,3), being 72.1% female.
Mean hospitalization costs per patientwere $BRL4,036 (SD 2,063) for the population
analyzed. VTE episodes were experienced by 42 patients (0,89%, 32 cases of DVT
and 10 of PE) and were associated with higher hospitalizations costs than patients
without any complication: $BRL3,919 (SD 1,811), $BRL4,581 (SD 2,362) and
$BRL7,715 (SD 6,777) for patients without complication, DVT and PE respectively.
CONCLUSIONS: Patients experiencing VTE following TKR surgery represents a sig-
nificant economic burden for the Brazilian public health care system. Our study
suggests that a patient who presents PE following TKR surgery can cost twicemore
than a patient without complications.
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OBJECTIVES: Hypertension is the most important risk factor in the preventable
cardiovascular risks. In the study, consumption analysis of the products contains
ARB and ACEI was performed and factors effecting the budget chance was calcu-
lated with a regression analysis for assessment the current situation.METHODS:A
computer base analysis was conducted depending on consumption data of ARB
and ACEI which were taken from Information Medical Statisticis – Health (IMS) in
2005-2010 years by using Windows Office Excel 2007. Regression analysis was per-
formed with the results of conducted analysis by using SPSS 15.00 for Windows.
RESULTS: Losartan consumption in unit, however, was rised 40%, consumption in
TL was decreased 47% in years. Consumption of Ramipril molecule in unit rised
71,2% and TL consumption decreased 31,7% from year 2005 to 2010, even the pos-
itive marketing effects of new generic molecules were launched. It was shown in
the regression analysis that new launched generics had a negative effect to budget
of ARB and ACEI. The formula of percentage chance of the budget of ARB and ACEI
market was calculated as PCB  NPLY*(-0,07)  PCY*(1,248)  CC*(0,936). BC: Per-
centage Chance of Budget, NPLY: New Product Number Launched in Years, PCY 
Percentage Chance of Price in Years, CC  Percentage Chance of Consumption in
Years. CONCLUSIONS: Effect of hypertension to Turkey‘s health budget is rising
day by day due both rising diagnosis and comorbidites. On the other hand, it was
shown that launching new generics has an important impact on controlling health
budget.
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OBJECTIVES: Aim of this study was to evaluate the average annual direct costs of
treating patients with a recent admission for acute coronary syndrome (ACS).
METHODS: Direct medical costs of patients with ACS (index event) in the period
January 1, 2008 to December 31, 2008 and treated with dual antiplatelet therapy
(clopidogrelaspirin)were estimated in a one-year follow-upperiod. Resource con-
sumption measured were: reimbursed drugs, diagnostic procedures, hospitaliza-
tions. The analysis was performed from the Italian National Health Service (INHS)
perspective. RESULTS: A total of 2,758,872 subjects were observed; 7,082 (35.8%
females) of thesewere hospitalized for ACSduring the 1-year accrual period (2.6‰).
Among patients with ACS, 60% were medically treated, 33.1% were treated with
percutaneous coronary intervention (PCI) and 6.9% died during the first hospital-
ization. Dual antiplatelet treatment was prescribed in 25.9% of patients with ACS
medically treated and in 70.1% of patients with ACS treated with PCI. During fol-
low-up, all-cause mortality rate was 5.7% [33% for cardiovascular (CV) causes];
among the 58.6% of patients with at least one re-hospitalization, 18.4% had a re-
current episode of ACS, 24.8% had other CV episodes and 15.4% were hospitalized
for non-CV reasons. Average yearly cost/patient for total ACS population was
12,673€/year (drugs: 1,896€, hospitalizations: 10,315€, diagnostic: 462€). For patients
with an index event of ACS medically treated, average annual cost was 11,043€/
year (drugs: 1,968€, hospitalizations: 8,558€, diagnostic: 517€) and for patients with
ACS treated with PCI, average annual cost per patient was 13,776€/year (drugs:
1,848€, hospitalizations: 11,492€, diagnostic: 436€). Hospitalization costs of patients
with a relapse were at least 49% higher than for patients without events. Patients
died for a CV event during follow-up had an average cost of 19,198€/patient.
CONCLUSIONS: Patients with ACS had relevant costs of management being the
need for a new hospitalization the major cost driver.
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OBJECTIVES: Traditionally, newly referred naïve anticoagulation patients (warfa-
rin use for2 months) received anticoagulation education via 30-min face-to-face
pharmacist counseling (Method I).We hypothesized that a new education program
with 15-min video education plus 15-min face-to-face pharmacist counseling
(Method II) would maximize operational revenues via increased scheduling capac-
ity leading to increased clinic visits while maintaining clinic efficiency and quality
education. This study aimed to compare operational revenues, clinical outcomes
and anticoagulation knowledge levels in patients receiving two anticoagulation
education methods. METHODS: This IRB-approved study employed a parallel-
group, pre-post design. Knowledge levels were evaluated using the previously val-
idated Short-form Oral Anticoagulation Knowledge Test (SOAK) before and after
education. Revenues and clinical outcomes were measured during the implemen-
tation of Method I or II. A sample size of 106 patients was required to detect a 15%
change in knowledge with 80% power and alpha of 0.05. RESULTS: There were 108
patients (Method I:II54:54) with similar baseline demotaphics: female (52.3%),
65 years-old (52.8%) and high school education (67.9%). Clinical measures re-
main stable between twoMETHODS:major bleeding rate (0.3%), thromboembolism
rate (0.4%) and patients within target INR (63%). A 3.39% increased monthly rev-
enues was observed in Method II compared to Method I, due to increased clinic
visits (12.97%) among newly referred naïve patients, yet total patient volume of
other types decreased (-2.95%). The pre-visit SOAK scores were similar between
Methods (p0.383). Both Methods significantly improved SOAK scores (Method I:
pre 55.9%26%/post 75.8%21%, p0.001; Method II pre 60.4%26%/post
70.7%22%, p0.030). Mean changes in pre-post SOAK scores were significantly
higher in Method I (21%23%) than in Method II (10%23%, p0.011).
CONCLUSIONS: The new education program (Method ii) resulted in increased rev-
enues via increased clinic visits among newly referred patients. Improved antico-
agulation knowledge levels using Method II were acceptable without adverse im-
pacting on safety and clinical outcomes.
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OBJECTIVES: Pharmacists play an integral role in quality improvement programs
through medication therapy management services (MTM). This study estimates
the effect of a pharmacist-led and delivered MTM program on achieving Optimal
Diabetes Care (ODC). METHODS: The study included patients with diabetes who
receivedMTM services at Fairview Clinics during a 2007 demonstration project (n
121) and those invited to receive MTM services but opted out (n 103). Baseline
characteristicswere compared between the two groups. Rates of ODC for 2006, 2007
and 2008 were compared using McNemar’s test based on Minnesota Community
Measurement all-or-none 5-component (D5) ODC measure (HbA1c 7%;
LDL100mg/dl; blood pressure140/90mmHg; tobacco free; and daily aspirin use).
Linear and Nonlinear multivariate difference-in-differences (DID) estimation were
used to evaluate the impact of one-year exposure toMTMon each component of D5
ODCmeasure. RESULTS: The MTM group had more co-morbidities, more complex
medication regimens and a higher percentage of diabetes with complications
(p0.05). There was significant improvement in ODC rates for the MTM group in
2007 compared to 2006 (45.45%vs.21.49%, p0.001) and a significant decline in 2008
(45.45% vs. 25.62%, p0.0002). The control group showed a significant improve-
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